UPDATE - Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual MeetingGlobeNewsWire • 05/03/22
Passage Bio to Present Updated Imagine-1 Study Clinical and Biomarker Data at the American Society of Gene and Cell Therapy 25th Annual MeetingGlobeNewsWire • 05/02/22
Passage Bio Doses First Patient in Global Clinical Trial for Infantile Krabbe Disease, A Rare Fatal Pediatric ConditionGlobeNewsWire • 03/10/22
Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q4 2021 Results - Earnings Call TranscriptSeeking Alpha • 03/03/22
Passage Bio Reports Fourth Quarter and Full-Year 2021 Financial Results and Provides Recent Business HighlightsGlobeNewsWire • 03/03/22
Passage Bio to Report Fourth Quarter and Full-Year 2021 Financial Results on March 3, 2022GlobeNewsWire • 02/24/22
Passage Bio Presents New Interim Clinical Data for Patients with GM1 Gangliosidosis in Imagine-1 Study at 2022 WORLDSymposiumGlobeNewsWire • 02/11/22
Passage Bio to Showcase GM1 Gangliosidosis and Krabbe Clinical Programs at 2022 WORLDSymposium, February 7 – 11GlobeNewsWire • 01/31/22
Passage Bio Announces Positive Interim Safety and Biomarker Data and Advances Phase 1/2 Trial of PBGM01 in GM1 GangliosidosisGlobeNewsWire • 12/17/21
Moore Kuehn, PLLC Encourages Investors of Passage Bio, Inc. to Contact Law FirmNewsfile Corp • 11/30/21
Passage Bio, Inc. (PASG) CEO Bruce Goldsmith on Q3 2021 Results - Earnings Call TranscriptSeeking Alpha • 11/06/21
Passage Bio Reports Third Quarter 2021 Financial Results and Provides Recent Business HighlightsGlobeNewsWire • 11/04/21
Passage Bio Announces Maxine Gowen, Ph.D., as Chairwoman of the Board of DirectorsGlobeNewsWire • 09/07/21
Passage Bio, Inc. (PASG) Bruce Goldsmith on Q2 2021 Results - Earnings Call TranscriptSeeking Alpha • 08/08/21
Passage Bio Mourns the Sudden Passing of Chairman of the Board Tadataka Yamada, M.D.GlobeNewsWire • 08/05/21